Forest Devices Announces Positive Study Results for Their Stroke Detection Technology
23.2.2021 18:00:00 EET | Business Wire | Press release
Medical technology pioneer Forest Devices, Inc. (FDI) today announced the publication of positive results from the EDGAR study of its AlphaStroke™ technology in identifying patients with large vessel occlusive (LVO) strokes in emergency departments in the American Heart Association Journal, STROKE. LVOs are the type of ischemic stroke that require an interventional thrombectomy, only available at highly specialized hospitals, and every minute of treatment delay increases the risk of death and permanent disability.
The study showed that, compared to the clinical exams currently used by medics in the field to make triage decisions, AlphaStroke was 28% - 40% superior at correctly identifying patients with LVO, and equally good as the clinical exams, at correctly ruling out patients with non-LVO diagnoses.
“The results from the EDGAR study are a high-water mark in the global effort to improve early identification of patients needing thrombectomy,” said Matt Kesinger, CEO of FDI. “As a former EMT on ambulances, I experienced the challenge of correctly identifying stroke patients with only a few clinical exam questions. The EDGAR study is the first study, in which a portable technology, designed specifically for LVO identification, has been shown to outperform clinical exams currently applied by EMT’s worldwide.”
“The EDGAR study shows AlphaStroke™ has the potential to dramatically improve the detection of large vessel occlusion stroke in the prehospital environment,” said Dr. Paulina Sergot, lead author of the study and Emergency Medicine physician at Memorial Hermann hospital in Houston, Texas, one of the hospitals participating in the EDGAR study.
“This technology will be a game-changer in the prehospital,” said senior study author Dr. Frank Peacock, Vice Chair for Research of Emergency Medicine, Baylor College of Medicine. “Easy, fast, and more accurate than clinical impression for the diagnosis of LVO, using AlphaStroke™ on ambulances will mean more stroke victims getting to the right hospital as soon as possible. Time is brain, and fast treatment is the only thing that can prevent death or permanent disability from stroke.”
FDI’s diagnostic platform, AlphaStroke™, is designed to support prehospital healthcare providers in identifying stroke.
Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania and Calgary, Alberta that has developed AlphaStroke, the first prehospital stroke detection technology. The company strives to reduce functional disability from stroke by eliminating delays in stroke treatment.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005078/en/
Contact information
Carmelo R. Montalvo
412.404.3769
pr@forestdevices.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Data Center World Unveils the Inaugural Data Center World Europe 202610.6.2026 14:00:00 EEST | Press release
Data Center World, the premier event for the global data center ecosystem, unveils the launch of Data Center World Europe. Today, Data Center World Europe announces the Conference Agenda for the inaugural event. Over two days, Data Center World Europetackles the industry’s most urgent challenge: transforming Europe's data centre energy landscape. The event brings together leading operators, technologists, cloud providers, hyperscalers and energy management innovatorsto exchange actionable strategies and groundbreaking insights that drive measurable results. Attendees will leave equipped to overcome energy bottlenecks and drive the development of an AI-ready, sustainable future. Data Center World Europe takes place 13-14 October 2026 at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It will be co-located with the leading global network infrastructure event NetworkX. Register to attend here. Tara Gibb, Senior Director, Data Center World Europe said, “As the demand for A
SES to conduct share buyback transaction via acquisition of FDRs to meet obligations under its employee incentive programs10.6.2026 13:56:00 EEST | Press release
SES has decided to launch a buyback transaction for shares via acquisition of fiduciary depositary receipts (FDRs) to meet obligations under SES’s Equity Based Compensation Plan (EBCP). These FDRs will be repurchased on the basis of Article 430-15(3) of the law of 10 August 1915 on commercial companies, as amended, and will not be counted towards the 10% limit as authorized during the annual general meeting of shareholders held on April 2, 2026. Under this share buyback transaction via acquisitions of FDRs, SES may acquire up to 2,967,519 FDRs (ISIN LU0088087324) at market price for an aggregate amount not exceeding EUR 31,158,949.50. The share buyback transaction via acquisition of FDRs is expected to be completed before the date of the next annual general meeting of shareholders or sooner if the maximum number of repurchased shares is reached earlier. The buyback will be conducted in accordance with applicable rules and regulations, including the Market Abuse Regulation 596/2014 and
New Research Reveals the Next Wealth Management Divide: AI Rewards Firms Built to Scale10.6.2026 13:34:00 EEST | Press release
The next competitive divide in banking, wealth and asset management will not be defined by innovation alone, but by firms’ ability to scale it profitably. That is the central finding of new research that Objectway, a global wealthtech partner for banking, wealth and asset management firms, conducted in collaboration with FT Longitude, a specialist provider of thought leadership and research services. The report, Built to Scale, is based on a survey of 300 senior professionals across banks, wealth and asset managers in the UK, continental Europe and Canada. Altough digital transformation and AI adoption are advancing rapidly across the industry, many firms are struggling to translate investment into repeatable, profitable growth. The findings point to a market entering a new phase of competition, where scalable executionis becoming more important thaninnovation capacity alone. Reflecting on this shift, Luigi Marciano, Founder and Group CEO of Objectway, commented: “For years, the indust
From Cutting-Edge Research to Industry: Focused Energy Plans Spin-Off of Sourcelight10.6.2026 12:38:00 EEST | Press release
Following its successful USD 240 million financing round, Focused Energy is continuing to systematically advance the industrialization of laser fusion as its core business. At the same time, the company plans to consolidate its activities in the field of laser-driven radiation sources into an independent entity under the name Sourcelight. With this move, Focused Energy is laying the groundwork for the industrial transfer of selected technological building blocks emerging from its laser fusion development. The spin-off demonstrates how cutting-edge research can give rise to new industry: scientific excellence is translated into industrial applications with strong value creation and growth potential. Sourcelight is intended to bring the LDRS (Laser-Driven Radiation Sources) technology developed by Focused Energy into targeted industrial applications. The technology combines laser-driven high-energy X-rays and neutrons in a single system. This enables not only high-resolution imaging, but
Cosylab and Heron Neutron Medical Corp. Sign Letter of Intent to Advance Global Deployment of Accelerator-Based BNCT Systems10.6.2026 12:30:00 EEST | Press release
Cosylab and Heron Neutron Medical Corp. announced today, 10 June 2026, the signing of a Letter of Intent to establish a strategic framework for joint market development to support the global deployment of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) systems. The collaboration aims to accelerate the development and integration of sophisticated software solutions for use with AB-BNCT while strengthening AB-BNCT's international market access and business development. By combining Cosylab's proven expertise in mission-critical software and complex system integration with Heron's end-to-end BNCT platforms, the partnership aims to drive broader global clinical adoption of this highly targeted cancer treatment modality. "AB-BNCT is emerging as one of the most promising approaches for treating difficult-to-treat and recurrent cancers," said Mark Pleško, Chief Executive Officer of Cosylab. "This collaboration reinforces our strategic focus on advancing radiation therapy technologie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom